What is the net financial impact of this debt exchange on Guardant Health?

The exchange effectively reduced the principal amount of outstanding convertible debt by approximately $59.3 million ($659.3 million exchanged for $600 million). While the company is now incurring a 1.25% annual interest cost on the new notes, this is offset by the principal reduction and extended maturity, providing a more favorable debt profile.

Under what conditions can the new convertible notes be converted into stock?

Noteholders can convert their notes under specific events until November 15, 2030. From November 15, 2030, until shortly before maturity, noteholders can convert at any time. The company has the option to settle these conversions with cash, shares of common stock, or a mix of both.

What are the key terms regarding redemption or repurchase of the new notes?

Guardant Health cannot redeem the notes at its option before February 21, 2028. After this date, redemption is possible under specific conditions, primarily if the company's stock price exceeds 130% of the conversion price for a sustained period. Additionally, noteholders can require repurchase upon the occurrence of a 'Fundamental Change' event, such as certain business combinations or delisting.

What is the potential dilution risk associated with these new convertible notes?

The initial conversion rate allows for the issuance of up to approximately 13,017,960 shares of common stock. This represents potential dilution. However, the conversion premium of 35% indicates that the company is effectively issuing shares at a price significantly higher than the recent market price, which could be viewed as a more favorable form of financing than if the stock price were at or below the conversion price.

GH 8-K: Material Agreements, Financial Events & More

01—Abstract

Summary

Summary of the 8-K filed February 14, 2025. Cited figures are marked; the original filing is the authoritative source.

Guardant Health, Inc. (GH) announced a significant debt restructuring through privately negotiated exchange agreements, resulting in the issuance of $600 million^a aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (New Notes).

These New Notes were exchanged for approximately $659.3 million^b principal amount of its outstanding 0% Convertible Senior Notes due 2027. This transaction effectively reduced the principal amount of outstanding convertible debt by approximately $59.3 million while extending the maturity profile of a portion of its debt to 2031 and introducing a modest interest cost. Investors should note that the company has strategically extended its debt maturity and reduced its near-term debt principal.

The New Notes carry a 1.25% annual interest rate and are convertible into Guardant Health common stock at an initial conversion price of approximately $62.22^c per share, representing a conversion premium of about 35% to the stock price on February 6, 2025. This convertible note structure allows the company to potentially issue shares at a premium, which could mitigate dilution compared to a cash repayment, while also providing flexibility for future capital management.

02—Key points

Key Highlights

GH exchanged approximately $659.3 million of its 0% Convertible Senior Notes due 2027 for $600 million of new 1.25% Convertible Senior Notes due 2031, reducing principal debt by about $59.3 million.
The new notes mature on February 15, 2031, extending the maturity of a portion of the company's convertible debt.
The new notes carry a 1.25% annual interest rate, payable semi-annually, compared to the previous 0% interest rate.
Conversion into GH common stock is possible at an initial rate of 16.0716 shares per $1,000 principal, equating to an initial conversion price of approximately $62.22 per share.
This conversion price reflects a premium of approximately 35% to the stock price on February 6, 2025.
The company can elect to settle conversions with cash, stock, or a combination, offering financial flexibility.
The new notes are senior unsecured obligations and have provisions for redemption, repurchase upon Fundamental Change events, and standard Events of Default.

03—Questions

Frequently Asked Questions

What is the net financial impact of this debt exchange on Guardant Health?
The exchange effectively reduced the principal amount of outstanding convertible debt by approximately $59.3 million ($659.3 million exchanged for $600 million). While the company is now incurring a 1.25% annual interest cost on the new notes, this is offset by the principal reduction and extended maturity, providing a more favorable debt profile.
Under what conditions can the new convertible notes be converted into stock?
Noteholders can convert their notes under specific events until November 15, 2030. From November 15, 2030, until shortly before maturity, noteholders can convert at any time. The company has the option to settle these conversions with cash, shares of common stock, or a mix of both.
What are the key terms regarding redemption or repurchase of the new notes?
Guardant Health cannot redeem the notes at its option before February 21, 2028. After this date, redemption is possible under specific conditions, primarily if the company's stock price exceeds 130% of the conversion price for a sustained period. Additionally, noteholders can require repurchase upon the occurrence of a 'Fundamental Change' event, such as certain business combinations or delisting.
What is the potential dilution risk associated with these new convertible notes?
The initial conversion rate allows for the issuance of up to approximately 13,017,960 shares of common stock. This represents potential dilution. However, the conversion premium of 35% indicates that the company is effectively issuing shares at a price significantly higher than the recent market price, which could be viewed as a more favorable form of financing than if the stock price were at or below the conversion price.

04—Continue

← View all 8-K filings